# US 2024/0376161 A1 · Recombinant chimeric protein, use thereof, and composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0376161 A1
- Document ID: US20240376161A1
- Status: Published application
- Kind: A1
- Application number: 18/564,843
- Filed: 2022-05-03
- Published: 2024-11-14
- Earliest claimed: 2021-05-28
- Applicants: FundaçãO Oswaldo Cruz
- Inventors: Ricardo Tostes Gazzinelli; Júlia Teixeira de Castro; Caroline Furtado Junqueira; Santuza Maria Ribeiro Teixeira; Ana Paula Salles Moura Fernandes
- Web page: https://patentgrep.com/patent/US20240376161A1

## CPC

- C07K 14/44: from protozoa
- A61K 39/005: Trypanosoma antigens
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/575: {humoral response}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a recombinant chimeric protein containing immunogenic regions from the trans-sialidase (TS) protein and amastigote surface protein-2 (ASP-2) from Trypanosoma cruzi and a composition containing said protein that displayed vaccine potential in a murine model. The invention also comprises the use of the chimeric protein for manufacturing vaccines.

## Claims

### Claim 1

Chimeric protein characterized by comprising a peptide sequence with at least 80% identity with the SEQ ID No 1.

### Claim 2

Chimeric protein characterized by comprising the peptide sequence of SEQ ID No 1.

### Claim 3 (depends on 1, 2)

Use of a chimeric protein, as defined in claim 1 or 2, characterized by being for the manufacture of a composition for the prevention and/or treatment of an infection by Trypanosoma cruzi.

### Claim 4 (depends on 3)

Use, according to claim 3, characterized by the composition being a vaccine.

### Claim 5 (depends on 3, 4)

Use, according to claim 3 or 4, characterized by the Trypanosoma cruzi infection being Chagas disease.

### Claim 6 (depends on 1, 2)

Composition characterized by comprising a chimeric protein, as defined in claim 1 or 2, and adjuvants.

### Claim 7 (depends on 6)

Composition, according to claim 6, characterized by being a vaccine.

### Claim 8 (depends on 6, 7)

Composition, according to claim 6 or 7, characterized by the adjuvants being selected from the group comprising CpG, aluminum hydroxide; monophosphoryl lipid A (MPL); polyinosinic-polycytidylic acid; and compositions containing mineral oils, vegetable oils, animal oils, compounds derived therefrom and/or combinations thereof.

### Claim 9 (depends on 6, 7, 8)

Composition, according to any one of claims 6 to 8, characterized by comprising:
1 to 500 μg of said protein:
10 to 500 μg/mL of CpG, preferably 180 μg/mL; and
20 a 40% v/v of aluminum hydroxide, preferably 30% v/v.

### Claim 10 (depends on 6, 7, 8)

Composition, according to any one of claims 6 to 8, characterized by comprising:
1 to 500 μg of said protein: and
100 to 1000 μg/mL of polyinosinic-polycytidylic acid, preferably 500 μg/mL.
